- August 20, 2018
- Posted by: PharmaScroll
As per a new study, conducted on a limited number of patients, patients have shown high level of satisfaction from the current IV treatment conditions. Multiple sclerosis (MS) treatment aims not only to prevent the rate of relapse, but also to slow down patient’s disability progression. Monoclonal antibodies constitute a new class of therapeutic agents and are administered by intravenous (IV) infusion. Treatment satisfaction and incidence of adverse drug events influence the patient’s treatment adherence which is essential to ensure patients obtain the best treatment outcomes and also to make that treatment cost-effective. The study was aimed at assessing the current IV treatment satisfaction among MS patients.
A standard questionnaire was developed which contained 20 questions about patient’s disease, IV treatment satisfaction and drug safety awareness. Analyzed data was presented as a percent of the respondents.
Results of the study:
The cross-sectional study included 13 MS patients on IV treatment, with mean age of 35 years. 54% of them had relapse-remitting MS, while 46% had secondary progressive MS. The most common onset symptoms were tingling reported in 46% and numbness in 31% patients. 70% of patients were satisfied, while 23% were not satisfied with the conditions under which they were receiving their IV treatment that lasts in average 2 hours. Well-established pharmacovigilance practice enhanced the patient’s knowledge that was reflected through 100% reporting of adverse drug reactions in the past.
The study concluded that high level of satisfaction from the current IV treatment conditions and high drug safety awareness among MS patients was shown. The study further highlighted that establishment of infusion centre as a proposed strategy by MS patients would substantially increase their IV treatment satisfaction and adherence.
Pharmascroll is a diligent business consulting and market research firm focused solely towards pharmaceutical markets. The company consults and researches in majorly chronic disease indications prevalent across the globe. The research conducted by Pharmascroll analysts is targeted to provide analytical and logical answers to the key business questions of the pharmaceutical and medical insights teams and to make better informed business decisions with the detailed relevant information available.
To read more news about Multiple Sclerosis, visit https://pharmascroll.com/news-category/multiple-sclerosis/
News Source: https://content.sciendo.com/view/journals/prilozi/39/1/article-p115.xml
Image Source: http://nursingtopics.com/intravenous-therapy-iv-insertion/